Revvity stock (US76155R1086): FDA clearance for testosterone assay, Q1 earnings beat

Revvity, a provider of life sciences and diagnostics solutions, announced FDA clearance for its total testosterone assay, enabling a comprehensive automated testing portfolio, Morningstar via Business Wire as of 05/13/2026. This regulatory approval strengthens its diagnostics offerings amid recent Q1 earnings that topped expectations.

Revvity reported Q1 2026 earnings on May 5, 2026, with EPS of $1.06 versus consensus $1.02 and revenue of $711.1 million, up 7% year-over-year from $664.8 million, MarketBeat as of 05/07/2026. The stock trades at $98.74 on NYSE:RVTY as of May 13, 2026, up 2% year-to-date.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Revvity: core business model

Revvity develops technology-enabled solutions for life sciences, diagnostics, and applied markets. Its portfolio includes instruments, reagents, and software for drug discovery, diagnostics, and research applications. The company serves pharmaceutical, biotech, academic, and clinical customers worldwide, with a focus on US markets where diagnostics demand is high.

Revenue stems from recurring consumables and services alongside capital equipment sales. In Q1 2026, total revenue reached $711.1 million, reflecting strength in discovery and diagnostics segments as reported in its 10-Q filing, GuruFocus as of 05/2026.

Main revenue and product drivers for Revvity

Diagnostics represent a key driver, bolstered by the new FDA-cleared total testosterone assay, part of a chemiluminescent immunoassay (ChLIA) portfolio. This approval enables automated, comprehensive testosterone testing, addressing clinical needs in endocrinology. Life sciences tools for genomics and proteomics also contribute significantly.

Financials show net margins of 8.26% and return on equity of 8.00% trailing twelve months, per MarketBeat data as of May 2026. A $1 billion share repurchase program authorized October 27, 2025, underscores capital return focus.

Industry trends and competitive position

The diagnostics sector benefits from rising automation and precision medicine demands in the US. Revvity competes with Bruker and others, holding an edge in net margins at 8.26% versus peers, MarketBeat as of 05/13/2026. Its GF Score of 79/100 signals solid fundamentals.

Why Revvity matters for US investors

Listed on NYSE, Revvity offers US investors exposure to growing life sciences and diagnostics markets. With strong Q1 results and FDA wins, it aligns with healthcare innovation trends impacting the US economy.

Conclusion

Revvity's FDA clearance and Q1 earnings beat highlight operational momentum in diagnostics and life sciences. With a buyback program and solid margins, the company maintains financial resilience. US investors track its NYSE performance amid sector growth, though market dynamics remain key.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.